LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,418,333
تعداد دریافت فایل اصل مقاله11,295,995
Shahverdi, Mahshid, Amri, Jamal, Karami, Hadi, Baazm, Maryam. (1400). Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide. سامانه مدیریت نشریات علمی, 46(4), 298-307. doi: 10.30476/ijms.2020.83173.1203
Mahshid Shahverdi; Jamal Amri; Hadi Karami; Maryam Baazm. "Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide". سامانه مدیریت نشریات علمی, 46, 4, 1400, 298-307. doi: 10.30476/ijms.2020.83173.1203
Shahverdi, Mahshid, Amri, Jamal, Karami, Hadi, Baazm, Maryam. (1400). 'Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide', سامانه مدیریت نشریات علمی, 46(4), pp. 298-307. doi: 10.30476/ijms.2020.83173.1203
Shahverdi, Mahshid, Amri, Jamal, Karami, Hadi, Baazm, Maryam. Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide. سامانه مدیریت نشریات علمی, 1400; 46(4): 298-307. doi: 10.30476/ijms.2020.83173.1203

Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide

Iranian Journal of Medical Sciences
مقاله 8، دوره 46، شماره 4، مهر 2021، صفحه 298-307    اصل مقاله (774.09 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.83173.1203
نویسندگان
Mahshid Shahverdi1، 2؛ Jamal Amri3؛ Hadi Karami* 4؛ Maryam Baazm5
1Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
2Department of Molecular Medicine and Biotechnology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
4Department of Molecular Medicine and Biotechnology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
5Department of Anatomy, School of Medicine, Arak University of Medical Sciences, Arak, Iran
چکیده
Background: Studies have shown that myeloid cell leukemia-1 (Mcl-1) is the target gene for microRNA -101 (miRNA-101), and decreased levels of miRNA-101 are associated with elevated levels of Mcl-1 and lung cancer survival. The objective of the present study was to investigate the effect of miRNA-101 on the sensitivity of A549 lung cancer cells to etoposide.
Methods: The study was conducted during 2018 and 2019 at Arak University of Medical Sciences, Arak, Iran. The effect of miRNA-101 on Mcl-1 expression was assessed using reverse transcription-quantitative polymerase chain reaction 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), and trypan blue exclusion assays were performed to determine the effect of treatments on cell survival and proliferation, respectively. The interaction between miRNA-101 and etoposide was evaluated using the combination index analysis of Chou-Talalay. Apoptosis was quantified using ELISA cell death assay. ANOVA and Bonferroni’s tests were used to determine statistical differences between the groups (p <0.05). GraphPad Prism software (version 6.01) was used for data analysis.
Results: The results showed that miRNA-101 clearly inhibited the expression of Mcl-1 and reduced the growth of A549 cells, relative to blank control and negative control miRNA (p <0.05). Transfection of miRNA-101 synergistically enhanced the sensitivity of the A549 cells to etoposide. Apoptosis assay data also showed that miRNA-101 triggered apoptosis and augmented the etoposide-mediated apoptosis.
Conclusion: Up-regulation of miRNA-101 inhibited cell survival and proliferation, and sensitized A549 cells to etoposide by suppressing Mcl-1 expression. miRNA-101 replacement therapy can be considered as an effective therapeutic strategy in non-small cell lung cancer.
کلیدواژه‌ها
Apoptosis؛ Etoposide؛ Lung neoplasms؛ Myeloid cell leukemia sequence 1 protein؛ MicroRNA-101
سایر فایل های مرتبط با مقاله
مراجع
  1. MacDonagh L, Gray SG, Finn SP, Cuffe S, O’Byrne KJ, Barr MP. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev. 2015;41:160-9. doi: 10.1016/j.ctrv.2014.12.009. PubMed PMID: 25592062.
  2. Zhang Y, Yang Q, Wang S. MicroRNAs: a new key in lung cancer. Cancer Chemother Pharmacol. 2014;74:1105-11. doi: 10.1007/s00280-014-2559-9. PubMed PMID: 25135624.
  3. Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ, Wang XL, et al. MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7. Oncotarget. 2015;6:30818-30. doi: 10.18632/oncotarget.5067. PubMed PMID: 26360780; PubMed Central PMCID: PMCPMC4741570.
  4. Yu Y, He J. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med. 2013;7:157-71. doi: 10.1007/s11684-013-0272-4. PubMed PMID: 23681892.
  5. Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers (Basel). 2019;11. doi: 10.3390/cancers11081087. PubMed PMID: 31370269; PubMed Central PMCID: PMCPMC6721450.
  6. Jan R, Chaudhry GE. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Adv Pharm Bull. 2019;9:205-18. doi: 10.15171/apb.2019.024. PubMed PMID: 31380246; PubMed Central PMCID: PMCPMC6664112.
  7. Shirjang S, Mansoori B, Asghari S, Duijf PHG, Mohammadi A, Gjerstorff M, et al. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radic Biol Med. 2019;139:1-15. doi: 10.1016/j.freeradbiomed.2019.05.017. PubMed PMID: 31102709.
  8. Gautrey HL, Tyson-Capper AJ. Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One. 2012;7:e51497. doi: 10.1371/journal.pone.0051497. PubMed PMID: 23284704; PubMed Central PMCID: PMCPMC3524227.
  9. Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A, et al. Flavonoids in Cancer and Apoptosis. Cancers (Basel). 2018;11. doi: 10.3390/cancers11010028. PubMed PMID: 30597838; PubMed Central PMCID: PMCPMC6357032.
  10. Indran IR, Tufo G, Pervaiz S, Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta. 2011;1807:735-45. doi: 10.1016/j.bbabio.2011.03.010. PubMed PMID: 21453675.
  11. Chen Y, Bao C, Zhang X, Lin X, Huang H, Wang Z. Long non-coding RNA HCG11 modulates glioma progression through cooperating with miR-496/CPEB3 axis. Cell Prolif. 2019;52:e12615. doi: 10.1111/cpr.12615. PubMed PMID: 31310044; PubMed Central PMCID: PMCPMC6797506.
  12. Wang F, Chan LW, Law HK, Cho WC, Tang P, Yu J, et al. Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases. Genomics. 2014;104:504-11. doi: 10.1016/j.ygeno.2014.09.004. PubMed PMID: 25257143.
  13. Sun B, Fan Y, Yang A, Liang L, Cao J. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-beta/Smad4 signalling pathway by down-regulating DLX1. J Cell Mol Med. 2019;23:5934-48. doi: 10.1111/jcmm.14402. PubMed PMID: 31298493; PubMed Central PMCID: PMCPMC6714137.
  14. Amri J, Molaee N, Baazm M, Karami H. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. Asian Pac J Cancer Prev. 2019;20:2781-7. doi: 10.31557/APJCP.2019.20.9.2781. PubMed PMID: 31554377; PubMed Central PMCID: PMCPMC6976848.
  15. Ricciuti B, Mecca C, Crino L, Baglivo S, Cenci M, Metro G. Non-coding RNAs in lung cancer. Oncoscience. 2014;1:674-705. doi: 10.18632/oncoscience.98. PubMed PMID: 25593996; PubMed Central PMCID: PMCPMC4278269.
  16. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010;46:2295-303. doi: 10.1016/j.ejca.2010.05.012. PubMed PMID: 20712078.
  17. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, et al. MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol. 2012;29:1681-6. doi: 10.1007/s12032-011-0085-8. PubMed PMID: 21993632.
  18. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135-42. doi: 10.1158/0008-5472.CAN-08-2886. PubMed PMID: 19155302.
  19. Chen S, Wang H, Ng WL, Curran WJ, Wang Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 2011;81:1524-9. doi: 10.1016/j.ijrobp.2011.05.031. PubMed PMID: 22014955.
  20. Marchetti F, Pearson FS, Bishop JB, Wyrobek AJ. Etoposide induces chromosomal abnormalities in mouse spermatocytes and stem cell spermatogonia. Hum Reprod. 2006;21:888-95. doi: 10.1093/humrep/dei416. PubMed PMID: 16311288.
  21. Liu L, Xiao L, Liang X, Chen L, Cheng L, Zhang L, et al. TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer. Oncol Rep. 2017;37:3597-605. doi: 10.3892/or.2017.5638. PubMed PMID: 28498400.
  22. Pirayesh Islamian J, Mohammadi M, Baradaran B, Farajollahi A, Aghamiri SM, Asghari Jafarabadi M, et al. Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal squamous carcinoma cell lines by Hdm2-siRNA targeted gene therapy in vitro. Bioimpacts. 2016;6:93-8. doi: 10.15171/bi.2016.13. PubMed PMID: 27525226; PubMed Central PMCID: PMCPMC4981254.
  23. Amri J, Molaee N, Karami H. Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells. Asian Pac J Cancer Prev. 2019;20:3361-7. doi: 10.31557/APJCP.2019.20.11.3361. PubMed PMID: 31759360; PubMed Central PMCID: PMCPMC7062986.
  24. Yin J, Wang M, Jin C, Qi Q. miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett. 2014;7:461-5. doi: 10.3892/ol.2013.1725. PubMed PMID: 24396470; PubMed Central PMCID: PMCPMC3881938.
  25. Wang H, Wang L, Zhang G, Lu C, Chu H, Yang R, et al. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget. 2018;9:7501-12. doi: 10.18632/oncotarget.23483. PubMed PMID: 29484127; PubMed Central PMCID: PMCPMC5800919.
  26. Zhang X, He X, Liu Y, Zhang H, Chen H, Guo S, et al. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 2017;93:1065-73. doi: 10.1016/j.biopha.2017.07.005. PubMed PMID: 28738500.
  27. Chen Q, Liu D, Hu Z, Luo C, Zheng SL. miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6. Onco Targets Ther. 2019;12:835-48. doi: 10.2147/OTT.S184235. PubMed PMID: 30774371; PubMed Central PMCID: PMCPMC6355169.
  28. Han L, Chen W, Xia Y, Song Y, Zhao Z, Cheng H, et al. MiR-101 inhibits the proliferation and metastasis of lung cancer by targeting zinc finger E-box binding homeobox 1. Am J Transl Res. 2018;10:1172-83. PubMed PMID: 29736210; PubMed Central PMCID: PMCPMC5934576.
  29. Zheng HB, Zheng XG, Liu BP. miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2. Int J Clin Exp Med. 2015;8:20263-70. PubMed PMID: 26884939; PubMed Central PMCID: PMCPMC4723784.
  30. Wei SH, Dong K, Lin F, Wang X, Li B, Shen JJ, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62:1055-64. doi: 10.1007/s00280-008-0697-7. PubMed PMID: 18297287.
  31. Greaves G, Milani M, Butterworth M, Carter RJ, Byrne DP, Eyers PA, et al. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both Mcl-1 and BCL-XL. Cell Death Differ. 2019;26:1037-47. doi: 10.1038/s41418-018-0183-7. PubMed PMID: 30185825; PubMed Central PMCID: PMCPMC6748112.
  32. Yamaguchi R, Lartigue L, Perkins G. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther. 2019;195:13-20. doi: 10.1016/j.pharmthera.2018.10.009. PubMed PMID: 30347215.
  33. Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27-36. doi: 10.1038/cdd.2017.161. PubMed PMID: 29099483; PubMed Central PMCID: PMCPMC5729526.
  34. Hadji A, Schmitt GK, Schnorenberg MR, Roach L, Hickey CM, Leak LB, et al. Preferential targeting of Mcl-1 by a hydrocarbon-stapled BIM BH3 peptide. Oncotarget. 2019;10:6219-33. doi: 10.18632/oncotarget.27262. PubMed PMID: 31692812; PubMed Central PMCID: PMCPMC6817437.
  35. Chen W, Bai L, Wang X, Xu S, Belinsky SA, Lin Y. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol. 2010;77:416-23. doi: 10.1124/mol.109.061226. PubMed PMID: 19933775; PubMed Central PMCID: PMCPMC2835422.
  36. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, et al. Modulation of NOXA and Mcl-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res. 2012;18:783-95. doi: 10.1158/1078-0432.CCR-11-1166. PubMed PMID: 22173547.
  37. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011;20:1397-411. doi: 10.1517/13543784.2011.609167. PubMed PMID: 21851287; PubMed Central PMCID: PMCPMC3205956.
  38. Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, et al. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Mol Pharmacol. 2019;96:419-29. doi: 10.1124/mol.119.116855. PubMed PMID: 31467029; PubMed Central PMCID: PMCPMC6726458.
  39. Shen Q, Li J, Mai J, Zhang Z, Fisher A, Wu X, et al. Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis. Cell Death Dis. 2018;9:986. doi: 10.1038/s41419-018-1040-9. PubMed PMID: 30250075; PubMed Central PMCID: PMCPMC6155218.
  40. Lian BSX, Yek AEH, Shuvas H, Abdul Rahman SF, Muniandy K, Mohana-Kumaran N. Synergistic anti-proliferative effects of combination of ABT-263 and Mcl-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res Notes. 2018;11:197. doi: 10.1186/s13104-018-3302-0. PubMed PMID: 29580266; PubMed Central PMCID: PMCPMC5870236.
آمار
تعداد مشاهده مقاله: 4,642
تعداد دریافت فایل اصل مقاله: 2,986


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب